N.V. Lyubimova, A.E. Kuzminov, A.V. Lebedeva,
Yu.S. Timofeev, M.G. Toms, I.S. Stilidi, N.E. Kushlinskii
N.N. Blokhin National Medical Research Center of Oncology,
Kashirskoe shosse, 23, Moscow, 115522, Russian Federation

Introduction. Small cell lung cancer (SCLS) is a highly aggressive type of tumor, and various compounds are considered as potential biochemical markers of its prognosis, including neuron-specific enolase (NSE), chromogranin A (CgA), and prograstrin releasing peptide (proGRP). The aim of the study. Analysis of basal serum concentrations of biochemical markers proGRP, NSE, and CgA association with the prognosis of progression-free survival in patients with SCLC. Methods. 62 patients with late-stage SCLC (III-IV) who received treatment using modern chemotherapy schemes was included in our investigation. Progression-free survival was analyzed from the start of the first course of chemotherapy to the detection of progression. ProGRP and NSE detection in blood serum was performed on the automatic biochemical analyzer Cobas e601 (Roche). CgA analysis was performed with ELISA method (Eurodiagnostica). Results. The medians of all studied markers were statistically significantly different from the control. We revealed an association between basal serum levels of proGRP and progression-free survival in patients with SCLC (p=0.0039); while in the group of patients with proGRP levels over 1384 pg/ml, the prognosis was less favorable. Survival analysis using NSE levels showed that in the group of patients with SCLC with levels above 72.9 ng/ml, the survival prognosis was less favorable (p=0.015). The simultaneous increase of proGRP and NSE secretion was a prognostically unfavorable factor. Conclusion. ProGRP and NSE can be used as predictors of progression-free survival in patients with advanced SCLC, and high marker levels were associated with an unfavorable prognosis.
small cell lung cancer, proGRP, NSE, CgA, biochemical marker, survival prognosis

Список литературы: 
  1. Bichkov M.B. Small cell lung cancer. M.: Pharmus Print Media; 2013; 263 (in Russian)]
  2. Li J., Dai C.H., Chen P., Wu J.N., Bao Q.L., Qiu H., Li X.Q. Survival and prognostic factors in small cell lung cancer. Med. Oncol. 2010; 27 (1): 73–81. DOI: 10.1007/s12032-009-9174-3
  3. Petrovic M., Bukumiric Z., Zdravkovic V., Mitrovic S., Atkinson H.D., Jurisic V. The prognostic significance of the circulating neuroendocrine markers chromogranin A, pro-gastrin-releasing peptide, and neuron-specific enolase in patients with small-cell lung cancer. Med. Oncol. 2014; 31 (2): 823. DOI: 10.1007/s12032-013-0823-1
  4. Harmsma M., Schutte B., Ramaekers F.C. Serum markers in small cell lung cancer: opportunities for improvement. Biochim. Biophys. Acta. 2013; 1836 (2): 255–72. DOI: 10.1016/j.bbcan.2013.06.002
  5. Liu X., Zhang W., Yin W., Xiao Y., Zhou C., Hu Y., Geng S. The prognostic value of the serum neuron specific enolase and lactate dehydrogenase in small cell lung cancer patients receiving first-line platinum-based chemotherapy. Medicine. 2017; 96 (46): 8258. DOI:10.1097/MD.0000000000008258
  6. Huang Z., Xu D., Zhang F., Ying Y., Song L. Pro-gastrin-releasing peptide and neuron-specific enolase: useful predictors of response to chemotherapy and survival in patients with small cell lung cancer. Clin. Transl. Oncol. 2016; 18 (10): 1019–25. DOI: 10.1007/s12094-015-1479-4
  7. Hirose T., Okuda K., Yamaoka T., Ishida K., Kusumoto S., Sugiyama T., Shirai T., Ohnshi T., Ohmori T., Adachi M. Are levels of pro-gastrin-releasing peptide or neuron-specific enolase at relapse prognostic factors after relapse in patients with small-cell lung cancer? Lung Cancer. 2011; 71 (2): 224–8. DOI: 10.1016/j.lungcan.2010.05.004
  8. Aluri V., Dilon J.S. Biochemical testing in neuroendocrine tumors. Endocrinol. Metab. Clin. North. Am. 2017; 46 (3): 669–77. DOI: 10.1016/j.ecl.2017.04.004
  9. Nordlund M.S., Fermer Ch., Nilsson O., Warren D.J., Paus E. Production and characterization of monoclonal antibodies for immunoassay of the lung cancer marker proGRP. Tumor Biol. 2007; 28: 100–10. DOI: 10.1159/000099335
  10. Molina R., Auge J.M., Bosch X., Escudero J.M., Vinolas N., Marrades R., Ramirez J., Carcereny E., Filella X. Usefulness of serum tumor markers, including progastrin-releasing peptide, in patients with lung cancer: correlation with histology. Tumor Biol. 2009; 30: 121–9. DOI: 10.1159/000224628
  11. Tutar N., Yetkin N.A., Yazici C., Onal O., Kontas O., Kelestemur F. Clinical significance of progastrin-releasing peptide, neuron-specific enolase, chromogranin a, and squamous cell cancer antigen in pulmonary neuroendocrine tumors. Turk. J. Med. Sci. 2019; 49 (3): 774–81. DOI: 10.3906/sag-1810-147
  12. Dong A., Zhang J., Chen X., Ren X., Zhang X. Diagnostic value of ProGRP for small cell lung cancer in different stages. J. Thorac. Dis. 2019; 1 (4): 1182–9. DOI: 10.21037/jtd.2019.04.29
  13. Cheng Y., He J., Zhang L., Chen X., Ou S. Evaluation of chemiluminescent immunoassay quantitative detection for pro-gastrin-releasing peptide (ProGRP) in serum and plasma. J. Int. Med. Res. 2020; 48 (4): 1–10. DOI: 10.1177/0300060519882802
  14. Nisman B., Nechushtan H., Biran H., Peled N., Gantz-Sorotsky H., Doviner V., Perelman M., Bar J., Onn A., Uziely B., Peretz T. New ARCHITECT plasma pro-gastrin-releasing peptide assay for diagnosing and monitoring small-cell lung cancer. Br. J. Cancer. 2016; 114 (4): 469–76. DOI: 10.1038/bjc.2016.7
  15. Lv Sh.P., Wang Y., Huang L., Wang F., Zhou J.G., Ma H. Meta-Analysis of Serum Gastrin-Releasing Peptide Precursor as a Biomarker for Diagnosis of Small Cell Lung Cancer. Asian Pac. J. Cancer Prev. 2017; 18 (2): 391–7. DOI: 10.22034/APJCP.2017.18.2.39